Original Article

You have full text access to this OnlineOpen article

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice

  1. Benjamin Ory M.D.1,
  2. Marie-Françoise Heymann M.D.2,
  3. Akira Kamijo M.D., Ph.D.3,
  4. François Gouin M.D., Ph.D.1,
  5. Dominique Heymann Ph.D.1,†,*,
  6. Françoise Redini Ph.D.1

Article first published online: 3 NOV 2005

DOI: 10.1002/cncr.21530

Issue

Cancer

Cancer

Volume 104, Issue 11, pages 2522–2529, 1 December 2005

Additional Information

How to Cite

Ory, B., Heymann, M.-F., Kamijo, A., Gouin, F., Heymann, D. and Redini, F. (2005), Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, 104: 2522–2529. doi: 10.1002/cncr.21530

Author Information

  1. 1

    Universite de Nantes EA 3822; INSERM ERI 7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, Nantes, France

  2. 2

    Departement de Pathologie, Hopital Nord Laennec, St. Herblain, France

  3. 3

    Department of Orthopedic Surgery, Yokohama City University, School of Medicine, Yokohama, Japan

  1. †

    Fax: (011) 33 2 40 41 28 60

*Universite de Nantes EA 3822; INSERM ERI 7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France

  1. †

    Fax: (011) 33 2 40 41 28 60

Publication History

  1. Issue published online: 18 NOV 2005
  2. Article first published online: 3 NOV 2005
  3. Manuscript Revised: 11 AUG 2005
  4. Manuscript Accepted: 11 AUG 2005
  5. Manuscript Received: 14 JAN 2005

Funded by

  • Ministere de la Recherche. Grant Number: ACI TS/0220044
  • Comite des Pays de Loire de la Ligue Contre le Cancer

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (554K)

REFERENCES

  • 1
    Fleish H. Development of bisphosphonates. Breast Cancer Res. 2002; 4: 30–34.
  • 2
    Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88: 2095–2105.
  • 3
    Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004; 10: 337–343.
  • 4
    Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on bone and visceral metastases. Cancer Treat Res. 2004; 118: 213–229.
  • 5
    Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat. 2002; 75: 249–258.
  • 6
    Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10: 4559–4567.
  • 7
    Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol. 2002; 20: 3470–3477.
  • 8
    Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 1996; 56: 2434–2439.
  • 9
    Nitto H, Koshino T, Mitsugi N, Hiruma T. Growth of a murine osteosarcoma-derived cell sarcoma increases serum immunosuppressive acidic protein levels. Cancer J. 2000; 60: 5625–5629.
  • 10
    Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005; 37: 74–86.
  • 11
    Diel IJ, Solomayer E-F, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998; 339: 357–363.
  • 12
    Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G. Bisphosphonates in the reduction of metastases in breast cancer — results of the extended follow-up of the first study population. Proc ASCO 2001 (Abstr. 314).
  • 13
    McCloskey EV, Powles T, Paterson AHG, Ashley S, Kanis JA. Clodronate reduces incidence of skeletal metastases in women with primary breast cancer. Bone. 1998; 23: S189.
  • 14
    Saarto T, Blomqvist C, Virkkunen P, Eloma II. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomised controlled trial. J Clin Oncol. 2001; 19: 10–17.
  • 15
    Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995; 55: 3551–3557.
  • 16
    Stearns ME, Wang M. Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metastasis. 1996; 16: 116–131.
  • 17
    Sasaki A, Kitamura K, Alcade RE et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer. 1998; 77: 279–285.
    Direct Link:
  • 18
    Nobuyuki H, Hiraga T, Williams PJ, et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res. 2001; 16: S191.
  • 19
    Alvarez E, Galbreath EJ, Westmore M, et al. Properties of bisphosphonates in the 13762 syngenic rat mammary carcinoma model of tumor induced bone resorption. Proc Am Assoc Cancer Res. 2002; 43: 316.
  • 20
    Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol. 2003; 122: 202–210.
    Direct Link:
  • 21
    Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001; 28: 465–473.
  • 22
    Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone. 2003; 33: 216–228.
  • 23
    Forsea AM, Muller C, Riebeling C, Orfanos CE, Geilen CC. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer. 2004; 91: 803–810.
View Full Article (HTML) Get PDF (554K)